Table II.

Univariate analysis of progression-free prognostic factors in patients with endometrial carcinoma.

Factors	Patients	Univariate hazard ratio	95% CI	P-value	Multivariate hazard ratio	95% CI	P-value
FIGO stage
I	75
II, III, IV	33	2.8	1.0–7.7	0.0532	NA	NA	NA
Grade
G1, G2	79
G3	29	27.1	6.0–122.1	<0.0001	18.2	3.8–86.8	0.0003
Lymph node metastasis
Negative	93
Positive	15	9.7	3.4–27.7	<0.0001	NA	NA	NA
Depth (myometrial invasion)
a, b	67
c	41	8.824	2.5–31.4	0.0008	5.3	1.4–19.8	0.0142
Lymphovascular space invasion
Negative	62
Positive	46	30.5	4.0–233.6	0.001	NA	NA	NA
Menopause
Peri, pre	28
Post	80	5.5	0.7–42.0	0.0991	NA	NA	NA
Body mass index
<25	79
≥25	29	1.1	0.3–3.5	0.8597	NA	NA	NA
Age (years)
<60	54
≥60	54	2.9	0.9–9.1	0.069	NA	NA	NA
CCNE1 FISH
Normal	9
Amp	99	4.7	1.5–14.8	0.0081	2.2	0.6–7.4	0.2175
CCNE1 immunostaing
Low	54
High	54	1.7	0.6–4.8	0.3148	NA	NA	NA
FBXW7 immunostaing
Positive	45
Negative	63	1.9	0.6–5.5	0.2637	NA	NA	NA